Pascal Soriot: AstraZeneca 'on track' to hit big $40B goal, capping years-long turnaround campaign

For the past year or so, Covid-19 has dominated the narrative around AstraZeneca. And for good reason: The pharma giant has shipped 2.6 billion doses of its Oxford-partnered vaccine worldwide, and it’s been racking up new orders of Evusheld, a long-acting antibody designed to protect the 2% of the global population who are immunocompromised.